BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $226,000 | -32.9% | 467 | -47.1% | 0.01% | -38.9% |
| Q2 2021 | $337,000 | 0.0% | 882 | 0.0% | 0.02% | 0.0% |
| Q1 2021 | $337,000 | -3.4% | 882 | -19.7% | 0.02% | -5.3% |
| Q4 2020 | $349,000 | +46.0% | 1,098 | +13.9% | 0.02% | +26.7% |
| Q3 2020 | $239,000 | -6.3% | 964 | 0.0% | 0.02% | -11.8% |
| Q2 2020 | $255,000 | +15.9% | 964 | -16.8% | 0.02% | 0.0% |
| Q1 2020 | $220,000 | +5.8% | 1,158 | +22.3% | 0.02% | +30.8% |
| Q4 2019 | $208,000 | -91.7% | 947 | -96.5% | 0.01% | -90.8% |
| Q3 2018 | $2,506,000 | 0.0% | 27,360 | 0.0% | 0.14% | -4.1% |
| Q2 2018 | $2,506,000 | -7.4% | 27,360 | -4.6% | 0.15% | -9.3% |
| Q1 2018 | $2,707,000 | +8.0% | 28,690 | +4.9% | 0.16% | +11.0% |
| Q4 2017 | $2,506,000 | 0.0% | 27,360 | 0.0% | 0.15% | -5.2% |
| Q3 2017 | $2,506,000 | -7.7% | 27,360 | -6.1% | 0.15% | -8.9% |
| Q2 2017 | $2,714,000 | +8.3% | 29,130 | +6.5% | 0.17% | +11.2% |
| Q1 2017 | $2,506,000 | -7.9% | 27,360 | -7.1% | 0.15% | -10.6% |
| Q4 2016 | $2,722,000 | +1020.2% | 29,460 | +1227.0% | 0.17% | +844.4% |
| Q3 2016 | $243,000 | +11.5% | 2,220 | -5.7% | 0.02% | +12.5% |
| Q3 2015 | $218,000 | – | 2,355 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |